Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ajinomoto

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as subcutaneous formulation

Eisai said it aims to apply for US approval of SC Leqembi by the end of March 2024

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as a subcutaneous formulation

Leqembi was granted traditional approval in the US earlier this month as a bi-weekly intravenous infusion

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug granted full FDA approval

Leqembi was granted accelerated approval earlier this year for patients with early Alzheimer's disease

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug backed by FDA advisory committee for traditional approval

Leqembi was granted accelerated approval by the FDA in January for patients with early AD

- PMLiVE

MSD and Eisai’s combination therapy recommended by NICE for advanced endometrial cancer

More than 9,700 people are diagnosed with womb cancer each year in the UK

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug associated with positive long-term health outcomes

A simulation model estimated lecanemab to potentially slow the rate of disease progression

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration

US veterans in the early stages of the disease who meet VHA criteria will be eligible for coverage

- PMLiVE

FDA grants priority review for traditional approval of Biogen and Eisai’s Alzheimer’s drug

Leqembi was granted accelerated approval in the US earlier this year

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug receives FDA accelerated approval

An application has also been submitted for US approval under the traditional pathway

- PMLiVE

Eisai and Washington University to develop neurodegenerative disease therapies

Alzheimer’s will be a central focus for the new drug discovery collaboration

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug shown to slow memory decline in confirmatory study

The findings have been described as a ‘major step forward’ for dementia research

- PMLiVE

Biogen and Eisai’s lecanemab shows promise in confirmatory Alzheimer’s study

Results from the phase 3 trial showed reduction in clinical decline

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links